Therapy Areas: Respiratory
ILC Therapeutics Completes GBP 3.5m Funding Round
8 September 2021 - - UK-based biotechnology company ILC Therapeutics has completed a GBP 3.5m pre- IPO funding round, the company said.

Investors include Los Angeles-based lawyer and investor, Robert Kopple; St Andrews-based Eos Angel Investment Syndicate; Scottish Enterprise; ILCT management.

Alfacyte is ILCT's lead Hybrid interferon drug candidate and is being developed as an inhaled medicine to treat Respiratory Viral Infections including SARS CoV-2.

ILCT's Hybrid Interferons are designed by identifying selected favourable attributes of naturally occurring interferon subtypes and combining them together in a new class of novel Hybrid Interferons.

ILC's Hybrid Interferons are designed to provide enhanced efficacy and improved safety in comparison to their natural interferon subtypes.

In vitro testing has demonstrated that Alfacyte has many times greater antiviral activity against SARS-CoV-2 cell culture than any other available interferon.

ILC Therapeutics is an emerging biotechnology company focused on modulating the innate immune system through the design and development of novel hybrid interferon drug candidates.

Interferons are naturally produced chemical messenger molecules that 'interfere' with viral reproduction; they are the body's first and most powerful defence against all viral pathogens.

However, in many cases, and these include SARS, MERS and Covid-19, viruses evolve resistance mechanisms to evade or reduce natural interferon responses.

ILCT's Hybrid Interferons are designed by identifying selected favourable attributes of naturally occurring interferon subtypes and combining them together in a new class of novel Hybrid Interferons.

ILC's Hybrid Interferons will evade natural resistance and have the potential to provide enhanced efficacy and improved safety in comparison to the natural interferon subtypes.

The company was founded by Prof. W. H. Stimson FRSE, who established the Department of Immunology at The University of Strathclyde.

Eos invests through its Angel Syndicate, its EIS Innovation Fund and global Venture Partnerships. It also has Scottish Enterprise co-investment status.

Scottish Enterprise is Scotland's national economic development agency.
Login
Username:

Password:


Related Headlines